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Purpose/Objective(s)

Conclusion

Management options for meningioma include observation, surgical
resection, and radiation therapy (RT). In cases of progressive or
recurrent disease after RT, similar options exist. The control rate
following a second course of RT is unknown.

Reirradiation for recurrent or progressive meningioma yields
modest tumor control rates. Outcomes are poor in patients with
high-grade tumors.

Material/Methods
We reviewed an institutional database of patients treated with
stereotactic radiosurgery (SRS) or fractionated stereotactic
radiotherapy (fSRT) for meningioma. Patients who underwent two
or more courses of RT for disease recurrence or progression were
identified. Clinical, treatment, and outcome data for these patients
were recorded. Disease progression was defined as documented
growth on follow-up imaging or additional intervention.

Results
Six-hundred-fifty-one (651) patients were treated with RT for
meningioma from 1995 to 2009. Of those, 18 patients who underwent
reirradiation for recurrent or progressive meningioma and follow-up
imaging were identified. Thirteen (13) patients underwent surgical
resection before the first course of RT, and 6 patients underwent
surgical resection between courses of RT. Median interval between
courses of RT was 42 months (range 3-93). Ten (10) patients were treated
with SRS (14-18 Gy), and 8 were treated with fSRT (35.0-54.0 Gy).
With median follow-up time of 31 months (range 2-105), 11 patients
(61%) were found to progress after reirradiation, at a median of 10
months (range 5-57) following completion of treatment. KaplanMeier estimates of freedom from progression (FFP) at 1, 2, and 3
years were 65%, 65%, and 49%, respectively.
Seven patients (39%) were shown to have atypical or malignant
histology on biopsy or surgical resection at some point in their
treatment course. Median time to progression for these patients was
8 months. Median time to progression has not been reached for other
patients. FFP at 1 year for patients with atypical or malignant tumors
was 17%, compared to 90% for grade 1/unbiopsied tumors (p<0.01).
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